Outlook Therapeutics, Inc.

Historical 13F Holders

Symbol
OTLK
CUSIP
69012T305
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 69012T305 since 12/18/2024, largest first.

Filer % of Class Filed
GMS Ventures & Investments 13D/A
16.4% 8/14/2026
Event 8/12/2026
CVI Investments, Inc. 13G
9.9% 8/19/2026
Event 8/12/2026
Empery Asset Management, LP 13G
8.7% 10/13/2026
Event 9/30/2026
Tang Capital Partners LP 13G/A
6.4% 2/14/2025
Event 12/31/2024
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Intracoastal Capital LLC 13G
4.99% 4/24/2026
Event 4/22/2026
Great Point Partners, LLC 13G/A
4.99% 8/14/2025
Event 6/30/2025
Sphera Funds Management Ltd. 13G/A
4.7% 2/5/2026
Event 12/31/2025
Tang Capital Management LLC 13G/A
3.4% 8/14/2025
Event 6/30/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 14 908 k $520 k
2026 Q2 78 20.5 M $32.5 M
2026 Q1 62 10.7 M $2.21 M
2025 Q4 64 6.83 M $10.8 M
2025 Q3 62 4.08 M $4.33 M
2025 Q2 71 6.00 M $9.61 M
2025 Q1 68 7.09 M $8.65 M
2024 Q4 67 4.55 M $8.60 M
2024 Q3 72 7.94 M $42.4 M
2024 Q2 68 8.06 M $59.5 M
2024 Q1 58 7.27 M $86.6 M
2023 Q4 1 120 k $47.2 k
2023 Q3 2 228 k $50.9 k
2023 Q2 2 182 k $312 k
2023 Q1 2 179 k $192 k
2022 Q4 1 136 k $147 k
2022 Q3 1 113 k $140 k
2022 Q2 1 110 k $112 k
2022 Q1 1 101 k $186 k
2021 Q4 1 74.8 k $109 k
2021 Q3 1 52.3 k $113 k